PT-141 vs Tesamorelin

A melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Increasingly used off-label by men for libido and arousal.

An FDA-approved growth-hormone-releasing hormone analogue for HIV-associated lipodystrophy, used off-label for visceral fat reduction and metabolic health.

PT-141 (bremelanotide) activates central melanocortin receptors (MC3R/MC4R) rather than the vascular pathway targeted by PDE5 inhibitors like sildenafil. It acts on the brain's sexual-arousal circuitry.

Tesamorelin is a stabilised GHRH analogue with a longer half-life than sermorelin. It selectively reduces visceral adipose tissue (VAT) while preserving subcutaneous fat and lean mass.

1.75 mg subcutaneous on demand

1–2 mg subcutaneous daily

~2 hours (effects persist longer)

~26 minutes

Subcutaneous, Intranasal

Subcutaneous

approved

approved

£20 · £2.0/mg via Peptides UK

Not yet listed